181 related articles for article (PubMed ID: 19597081)
1. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.
Parashos SA; Swearingen CJ; Biglan KM; Bodis-Wollner I; Liang GS; Ross GW; Tilley BC; Shulman LM;
Arch Neurol; 2009 Sep; 66(9):1099-104. PubMed ID: 19597081
[TBL] [Abstract][Full Text] [Related]
2. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
Parashos SA; Luo S; Biglan KM; Bodis-Wollner I; He B; Liang GS; Ross GW; Tilley BC; Shulman LM;
JAMA Neurol; 2014 Jun; 71(6):710-6. PubMed ID: 24711047
[TBL] [Abstract][Full Text] [Related]
3. The impact of depressive symptoms in early Parkinson disease.
Ravina B; Camicioli R; Como PG; Marsh L; Jankovic J; Weintraub D; Elm J
Neurology; 2007 Jul; 69(4):342-7. PubMed ID: 17581943
[TBL] [Abstract][Full Text] [Related]
4. Rankin scale as a potential measure of global disability in early Parkinson's disease.
Simuni T; Luo ST; Chou KL; Fernandez H; He B; Parashos S
J Clin Neurosci; 2013 Sep; 20(9):1200-3. PubMed ID: 23810387
[TBL] [Abstract][Full Text] [Related]
5. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
; Beal MF; Oakes D; Shoulson I; Henchcliffe C; Galpern WR; Haas R; Juncos JL; Nutt JG; Voss TS; Ravina B; Shults CM; Helles K; Snively V; Lew MF; Griebner B; Watts A; Gao S; Pourcher E; Bond L; Kompoliti K; Agarwal P; Sia C; Jog M; Cole L; Sultana M; Kurlan R; Richard I; Deeley C; Waters CH; Figueroa A; Arkun A; Brodsky M; Ondo WG; Hunter CB; Jimenez-Shahed J; Palao A; Miyasaki JM; So J; Tetrud J; Reys L; Smith K; Singer C; Blenke A; Russell DS; Cotto C; Friedman JH; Lannon M; Zhang L; Drasby E; Kumar R; Subramanian T; Ford DS; Grimes DA; Cote D; Conway J; Siderowf AD; Evatt ML; Sommerfeld B; Lieberman AN; Okun MS; Rodriguez RL; Merritt S; Swartz CL; Martin WR; King P; Stover N; Guthrie S; Watts RL; Ahmed A; Fernandez HH; Winters A; Mari Z; Dawson TM; Dunlop B; Feigin AS; Shannon B; Nirenberg MJ; Ogg M; Ellias SA; Thomas CA; Frei K; Bodis-Wollner I; Glazman S; Mayer T; Hauser RA; Pahwa R; Langhammer A; Ranawaya R; Derwent L; Sethi KD; Farrow B; Prakash R; Litvan I; Robinson A; Sahay A; Gartner M; Hinson VK; Markind S; Pelikan M; Perlmutter JS; Hartlein J; Molho E; Evans S; Adler CH; Duffy A; Lind M; Elmer L; Davis K; Spears J; Wilson S; Leehey MA; Hermanowicz N; Niswonger S; Shill HA; Obradov S; Rajput A; Cowper M; Lessig S; Song D; Fontaine D; Zadikoff C; Williams K; Blindauer KA; Bergholte J; Propsom CS; Stacy MA; Field J; Mihaila D; Chilton M; Uc EY; Sieren J; Simon DK; Kraics L; Silver A; Boyd JT; Hamill RW; Ingvoldstad C; Young J; Thomas K; Kostyk SK; Wojcieszek J; Pfeiffer RF; Panisset M; Beland M; Reich SG; Cines M; Zappala N; Rivest J; Zweig R; Lumina LP; Hilliard CL; Grill S; Kellermann M; Tuite P; Rolandelli S; Kang UJ; Young J; Rao J; Cook MM; Severt L; Boyar K
JAMA Neurol; 2014 May; 71(5):543-52. PubMed ID: 24664227
[TBL] [Abstract][Full Text] [Related]
6. Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort.
Bega D; Kim S; Zhang Y; Elm J; Schneider J; Hauser R; Fraser A; Simuni T
J Parkinsons Dis; 2015; 5(4):773-82. PubMed ID: 26639661
[TBL] [Abstract][Full Text] [Related]
7. Barthel Index and modified Rankin Scale: Psychometric properties during medication phases in idiopathic Parkinson disease.
Taghizadeh G; Martinez-Martin P; Meimandi M; Habibi SAH; Jamali S; Dehmiyani A; Rostami S; Mahmuodi A; Mehdizadeh M; Fereshtehnejad SM
Ann Phys Rehabil Med; 2020 Nov; 63(6):500-504. PubMed ID: 31816448
[TBL] [Abstract][Full Text] [Related]
8. Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1.
Wills AM; Pérez A; Wang J; Su X; Morgan J; Rajan SS; Leehey MA; Pontone GM; Chou KL; Umeh C; Mari Z; Boyd J;
JAMA Neurol; 2016 Mar; 73(3):321-8. PubMed ID: 26751506
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.
NINDS NET-PD Investigators
Neurology; 2006 Mar; 66(5):664-71. PubMed ID: 16481597
[TBL] [Abstract][Full Text] [Related]
10. The clinically important difference on the unified Parkinson's disease rating scale.
Shulman LM; Gruber-Baldini AL; Anderson KE; Fishman PS; Reich SG; Weiner WJ
Arch Neurol; 2010 Jan; 67(1):64-70. PubMed ID: 20065131
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
12. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.
; Kieburtz K; Tilley BC; Elm JJ; Babcock D; Hauser R; Ross GW; Augustine AH; Augustine EU; Aminoff MJ; Bodis-Wollner IG; Boyd J; Cambi F; Chou K; Christine CW; Cines M; Dahodwala N; Derwent L; Dewey RB; Hawthorne K; Houghton DJ; Kamp C; Leehey M; Lew MF; Liang GS; Luo ST; Mari Z; Morgan JC; Parashos S; Pérez A; Petrovitch H; Rajan S; Reichwein S; Roth JT; Schneider JS; Shannon KM; Simon DK; Simuni T; Singer C; Sudarsky L; Tanner CM; Umeh CC; Williams K; Wills AM
JAMA; 2015 Feb; 313(6):584-93. PubMed ID: 25668262
[TBL] [Abstract][Full Text] [Related]
13. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
LeWitt P; Oakes D; Cui L
Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.
Perez-Lloret S; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Meissner WG; Schelosky L; Tison F; Rascol O
JAMA Neurol; 2014 Jul; 71(7):884-90. PubMed ID: 24839938
[TBL] [Abstract][Full Text] [Related]
16. Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
Schneider JS; Elm JJ; Parashos SA; Ravina BM; Galpern WR;
Parkinsonism Relat Disord; 2010 Sep; 16(8):507-12. PubMed ID: 20598621
[TBL] [Abstract][Full Text] [Related]
17. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
[TBL] [Abstract][Full Text] [Related]
18. Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial.
Parkinson Study Group STEADY-PD III Investigators
Ann Intern Med; 2020 May; 172(9):591-598. PubMed ID: 32227247
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Parkinson disease manifestations.
Perlmutter JS
Curr Protoc Neurosci; 2009 Oct; Chapter 10():Unit10.1. PubMed ID: 19802812
[TBL] [Abstract][Full Text] [Related]
20. Prediction of depression and anxiety via patient-assessed tremor severity, not physician-reported motor symptom severity, in patients with Parkinson's disease or essential tremor who have undergone deep brain stimulation.
Achey RL; Yamamoto E; Sexton D; Hammer C; Lee BS; Butler RS; Thompson NR; Nagel SJ; Machado AG; Lobel DA
J Neurosurg; 2018 Dec; 129(6):1562-1571. PubMed ID: 29473781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
